ArticleBritish journal of cancer2026

JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models.

Min Sil Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.